The Zhitong Finance App learned that Pfizer (PFE.US) announced on Wednesday that the US Food and Drug Administration (FDA) has approved its tyrosine kinase inhibitor Tukysa (tucatinib) as part of a combined treatment plan for first-line maintenance treatment of certain types of breast cancer.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.